Ann: Notice under ASX Listing Rule 3.10A, page-17

The management isnt perfect and they dont communicate much BUT more has turned around than the metrics.
If you look at the mix of sales and profit the business is definitely turning around. This sort of business takes time to turn around.
The last we heard in relation to one of the generic drugs recently released that was achieving very large sales was probably the beginning of the benefits of the non retail sales programme. The point remains, if you rode the teva share price rise you should have jumped off. If you bought in when the price was climbing to heaven it was a bad decision. Most purchases bought after the share price has taken off are bad.